FDA Sets New Goal For Biosimilar, Drug Promotion Guidances
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.
You may also be interested in...
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
Draft guidelines on interchangeability and statistical considerations due by end of 2017, suggesting long-awaited documents may not see the light of day this year as many had hoped.
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
Draft guidelines on interchangeability and statistical considerations due by end of 2017, suggesting long-awaited documents may not see the light of day this year as many had hoped.
FDA To Update Quality Metrics Guidance
It's the only addition to the agency's 2016 agenda.